FIELD: biotechnologies.
SUBSTANCE: phospholipide fluorescent probe characterised by the following name 1-[13-(4,4-difluoro-1,3,5,7-tetramethyl-4-bora-3a,4a-diaza-s-indacen-8-yl)tridecanoyl]-2-(10-{[(2-hydroxynaphthyl-1)azophenyl-4]azophenyl-4}decanoyl)-sn-glycero-3-phosphocholine, is used in the test system to determine activity of A2 phospholipase, group IIA (secFLA2(IIA)) in blood serum, which also contains vesicular and phospholipide matrix for inclusion of a probe, containing phosphatidyl choline, lisophosphatidyl choline and phosphatidyl glycerine, a buffer solution and A2 phospholipase of apitoxin as standard.
EFFECT: invention makes it possible to reliably detect activity of secFLA2 in human blood serum in clinical conditions.
2 cl, 5 dwg, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FLUORESCENT PROBE AND TEST-SYSTEM FOR DETERMINATION OF ACTIVITY OF A2 PHOSPHOLIPASE | 2012 |
|
RU2517746C1 |
| OBTAINING PHOSPHOLIPASE A2 GENE WITH CHANGED pH OPTIMUM BY REMOVING GLYCOSYLATION SITES | 2019 |
|
RU2766448C2 |
| DIRECT THROMBIN INHIBITOR, POSSESSING ANTIPROLIFERATIVE ACTION | 2007 |
|
RU2369615C2 |
| METHOD FOR PURIFYING A RECOMBINANT ENZYME PREPARATION OF PHOSPHOLIPASE A2 FROM A PRODUCER STRAIN PICHIA PASTORIS | 2019 |
|
RU2746563C1 |
| METHOD OF PREDICTING RISK OF DEVELOPMENT OF ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH CORONARY HEART DISEASE AND TYPE 2 DIABETES WITH PRIOR CORONARY ARTERY STENTING | 2015 |
|
RU2582291C1 |
| RECOMBINANT DNA pA4, RECOMBINANT DNA pQE 30-pA4, PROVIDING OBTAINING POLYPEPTIDE A4, Esherichia coli STRAIN M 15-A4, TRANSFORMED WITH RECOMBINANT PLASMID DNA pQE 30-pA4, AND EXPRESSING RECOMBINANT POLYPEPTIDE A4, RECOMBINANT POLYPEPTIDE A4, POSSESSING ABILITY TO SELECTIVELY BIND HSA, AFFINE SORBENTS (VERSIONS) AND METHODS FOR HSA AND IgG REMOVAL FROM BLOOD SERUM (VERSIONS) | 2014 |
|
RU2572343C2 |
| METHOD FOR CARRYING OUT TUBERCULOSTATIC TESTS IN PATIENTS WITH PULMONARY TUBERCULOSIS FOR LABORATORY SUBSTANTIATION OF PERSONIFIED TREATMENT | 2017 |
|
RU2686732C2 |
| METHOD FOR PREDICTING THE SEVERITY OF ACUTE PANCREATITIS AT AN EARLY STAGE BASED ON SIGNS OF HEPATODEPRESSION | 2017 |
|
RU2676331C1 |
| APITOXIN ALLERGENS AND ALLERGOIDS | 2008 |
|
RU2481122C2 |
| METHOD FOR DETERMINING BLOOD PLASMA COAGULATION INDICATORS - THROMBIN ACTIVITY, PLASMA RECALCIFICATION TIME AND PLASMA TOLERANCE TO HEPARIN | 2020 |
|
RU2786591C2 |
